Up to now, checkpoint inhibitors have been most effective in melanoma, bladder cancer and lung cancer. Other types of malignant disease where checkpoint inhibitors still have to prove their effectiveness should also be addressed by combining with trAb immunization. Therefore, the positive effect of blocking CTLA-4 during trAb vaccination on the CD4+ T cell-associated antitumor memory argues for further evaluation of this concept in preclinical and clinical settings.